ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00617734
Recruitment Status : Completed
First Posted : February 18, 2008
Results First Posted : April 17, 2018
Last Update Posted : April 17, 2018
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company

Brief Summary:
The purpose of this study is to determine if IMC-A12 alone or in combination with Cetuximab (Erbitux®) can increase the time prior to disease progression in participants with Squamous Cell Head and Neck Cancer who have had disease progression and platinum-containing chemotherapeutic regimen.

Condition or disease Intervention/treatment Phase
Head and Neck Cancer Biological: IMC-A12 (cixutumumab) Biological: cetuximab (Erbitux ®) Phase 2

Detailed Description:

The routine cancer treatments for Squamous Cell Carcinoma Head and Neck Cancer have improved but still leave a percentage of participants with incurable disease. New alternatives for participants whose disease is refractory to existing therapies is needed.

IMC-A12 is a monoclonal antibody which binds to special receptors known as insulin-like growth factor-I receptor (IGF-IR). This binding action has been shown to inhibit the growth of a variety of human tumor cell lines.

The purpose of this study is to evaluate the effects of IMC-A12 by itself or with Cetuximab (Erbitux®) in participants with Squamous Cell Carcinoma Head and Neck Cancer that has spread to other parts of the body, and to determine how long the drug remains in the body. The study will also look at what side effects IMC-A12 may cause when a participant is receiving treatment.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 97 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Phase 2 Open-Label Study of IMC-A12, as a Single Agent or in Combination With Cetuximab, in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Disease Progression on Prior Platinum-Based Chemotherapy
Study Start Date : March 2008
Actual Primary Completion Date : February 2012
Actual Study Completion Date : July 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Cetuximab
U.S. FDA Resources

Arm Intervention/treatment
Experimental: IMC-A12 (cixutumumab) Biological: IMC-A12 (cixutumumab)
IMC-A12 10 milligrams per kilogram (mg/kg) over one hour every two weeks. A cycle is defined as four weeks of therapy. Participants will continue on study until evidence of progressive disease, or unacceptable toxicity develops.
Other Names:
  • Cixutumumab
  • LY3012217
Experimental: IMC-A12 (cixutumumab) + cetuximab Biological: IMC-A12 (cixutumumab)
IMC-A12 10 milligrams per kilogram (mg/kg) over one hour every two weeks. A cycle is defined as four weeks of therapy. Participants will continue on study until evidence of progressive disease, or unacceptable toxicity develops.
Other Names:
  • Cixutumumab
  • LY3012217
Biological: cetuximab (Erbitux ®)
IMC-A12 10 mg/kg over one hour followed by cetuximab 500 milligrams per square meter (mg/m^2) over two hours. This sequence will be repeated every two weeks. Participants will continue on study until evidence of progressive disease or unacceptable toxicity develops.
Other Name: Erbitux®



Primary Outcome Measures :
  1. Progression-Free Survival (PFS) [ Time Frame: Baseline to measured PD (up to 27.66 months) ]
    PFS was defined as the interval from randomization until PD or death, whichever occurred first. Response was defined using Response Evaluation Criteria in Solid Tumors (RECIST, version 1.0) criteria. PD was defined as having at least a 20% increase in sum of the longest diameter of target lesions or the appearance of new lesions. PFS was censored at the date of the last objective progression-free disease assessment for participants who did not experience PD or death.


Secondary Outcome Measures :
  1. Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)] [ Time Frame: Baseline to measured PD (up to 27.66 months) ]
    ORR was defined as the percentage of participants achieving either CR or PR. Response was defined using RECIST, version 1.0 criteria. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions. Percentage of participants is calculated as a total number of participants with CR or PR divided by the total number of participants treated then multiplied by 100.

  2. Percentage of Participants With PFS at 6 Months [ Time Frame: 6 months ]
    PFS at 6 months was defined as the percentage of participants who have neither experienced PD nor died at 6 months after the date of randomization. Response was defined using RECIST, version 1.0 criteria. PD was defined as having at least a 20% increase in sum of the longest diameter of target lesions or the appearance of new lesions. Percentage of participants is calculated as the total number of participants with PFS at 6 months divided by the total number of participants treated then multiplied by 100.

  3. Overall Survival (OS) [ Time Frame: Baseline to date of death from any cause (up to 29.63 months) ]
    OS was defined as the duration from the date of randomization to the date of death from any cause. For participants who were alive, OS was censored at the date of last follow-up visit or at the date of last contact.

  4. Duration of Response [ Time Frame: Date of first response to the date of PD or death due to any cause (up to 23.98 months) ]
    The duration of CR or PR was defined as the time from first objective status assessment of CR or PR to the first time of PD or death. Response was defined using RECIST, version 1.0 criteria. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions. Duration of response was censored on the date of last tumor assessment for participants who were alive and have no evidence of PD.

  5. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Deaths [ Time Frame: Baseline through study completion (up to 29.63 months) ]
    TEAEs were defined as serious and other non-serious adverse events (AEs) that occurred or worsened after study treatment (regardless of causality). Data presented are the number of participants who experienced TEAEs including serious TEAEs, and deaths during the study including the 30-day follow-up. A summary of serious and other non-serious AEs regardless of causality is located in the Reported Adverse Events section of this report.

  6. Blood And Tissue Biomarkers And Development of Serum Antibodies Against IMC-A12 and Cetuximab [ Time Frame: Biomarkers [pre-dose, Cycle 1 (Day 15), (Cycle 2 (Day 1), and end of treatment]; Immunogenicity [pre-dose, prior to first infusion for Cycle 3, Cycle 5, and 30-day safety follow-up] ]
    No data for biomarkers and serum antibodies were collected due to lack of an appropriate validated assay.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically-confirmed squamous cell carcinoma of the oropharynx, hypopharynx, larynx, or oral cavity, metastasis or recurrence documented by clinical imaging studies
  • Measurable disease, lesion size ≥ 2 centimeters (cm) on conventional measurement techniques or ≥ 1 cm on spiral computed tomography (CT) scan
  • Clinical documentation of disease progression during treatment with or within 90 days after receiving the last cycle of platinum-based chemotherapy (with or without radiation therapy)
  • If prior treatment with anti-epidermal growth factor receptor (EGFR) therapy, the time to recurrence from last exposure to anti-EGFR therapy is > 90 days
  • Adequate hematologic function
  • Adequate hepatic function
  • Adequate coagulation function or is on a stable dose of an anticoagulant.
  • Adequate renal function
  • Fasting serum glucose <120 milligrams per deciliter (mg/dL) or below the upper limit of normal (ULN)
  • Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation

Exclusion Criteria:

  • Not recovered from adverse events due to agents administered more than 4 weeks earlier. Neurotoxicity, must have recovered to grade ≤ 2
  • Is receiving any other investigational agent(s)
  • History of treatment with other agents targeting the insulin-like growth factor receptor (IGFR)
  • Is receiving concurrent treatment with other anticancer therapy, including chemotherapy, immunotherapy, hormonal therapy, radiotherapy, chemoembolization, or targeted therapy
  • History of allergic reactions attributed to compounds of chemical or biologic composition similar to those of cetuximab or IMC-A12
  • Has poorly controlled diabetes mellitus. Participants with a history of diabetes mellitus are allowed to participate, provided that their blood glucose is within normal range (fasting < 120 mg/dL or below ULN) and that they are on a stable dietary or therapeutic regimen for this condition
  • Pregnant or breastfeeding
  • Is receiving therapy with immunosuppressive agents

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00617734


Locations
United States, California
ImClone Investigational Site
Orange, California, United States, 92868
United States, Florida
ImClone Investigational Site
Miami, Florida, United States, 33136
ImClone Investigational Site
Orlando, Florida, United States, 32806
United States, Georgia
ImClone Investigational Site
Atlanta, Georgia, United States, 30322
United States, Illinois
ImClone Investigational Site
Chicago, Illinois, United States, 60637
United States, Maryland
ImClone Investigational Site
Baltimore, Maryland, United States, 21231
United States, Massachusetts
ImClone Investigational Site
Boston, Massachusetts, United States, 02115
United States, Minnesota
ImClone Investigational Site
Rochester, Minnesota, United States, 55905
United States, New York
ImClone Investigational Site
Bronx, New York, United States, 10467
ImClone Investigational Site
New York, New York, United States, 10003
United States, Pennsylvania
ImClone Investigational Site
Pittsburgh, Pennsylvania, United States, 15232
United States, Tennessee
ImClone Investigational Site
Nashville, Tennessee, United States, 37232
United States, Texas
ImClone Investigational Site
Houston, Texas, United States, 77030
United States, Virginia
ImClone Investigational Site
Charlottesville, Virginia, United States, 22908
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company

Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT00617734     History of Changes
Other Study ID Numbers: 13913
CP13-0706 ( Other Identifier: ImClone, LLC )
CP02-0758 ( Other Identifier: ImClone, LLC )
I5A-IE-JAEB ( Other Identifier: Eli Lilly and Company )
First Posted: February 18, 2008    Key Record Dates
Results First Posted: April 17, 2018
Last Update Posted: April 17, 2018
Last Verified: March 2018

Keywords provided by Eli Lilly and Company:
Squamous Cell Carcinoma in Head and Neck
Prior Platinum-based chemotherapy
Cetuximab
Erbitux
IMC-A12

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Squamous Cell
Head and Neck Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Neoplasms by Site
Cetuximab
Antineoplastic Agents